Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715797 | 0.84 | TSHR (0.59) | TSHRMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL18266634 | 0.84 | MAPT (0.44) | TSHRMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL27805015 | 0.83 | ADORA1 (0.55) | TSHRMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL18266629 | 0.83 | MAPT (0.43) | TSHRMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL2713871 | 0.81 | CYP1A2 (0.58) | MAPTADORA3ADORA1CYP1A2SMN1; SMN2 | |
| SCHEMBL28945086 | 0.81 | TSHR (0.49) | TSHRMAPTADORA3ADORA2AADORA1 | |
| SCHEMBL1180020 | 0.80 | KMT2A (0.51) | TSHRMAPTCYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL2713671 | 0.78 | ADORA1 (0.51) | MAPTADORA3ADORA2AADORA1POLB | |
| SCHEMBL1180441 | 0.78 | MAPT (0.44) | TSHRMAPTCYP1A2SMN1; SMN2POLB | |
| SCHEMBL1178661 | 0.77 | KDM4E (0.57) | TSHRMAPTSMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | RAQUALIA PHARMA INC. (JP) | 2021-10-26 | — | — | US | disclosed |
| EP-3487839-B1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RAQUALIA PHARMA INC (JP) | 2020-12-23 | — | — | EP | disclosed |
| CN-106478497-B | Arylamine derivatives as TTX-S blockers | 拉夸里亚创药株式会社 | 2020-05-08 | — | — | CN | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| EP-3487839-A1 | AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | RaQualia Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| WO-2018235851-A1 | AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2018-12-27 | — | — | WO | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2630122-B1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9302991-B2 | Arylamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630122-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2013-08-28 | — | — | EP | disclosed |
| CN-103249721-A | Arylamine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC | 2013-08-14 | — | — | CN | disclosed |
| CN-101970430-B | Novel pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2013-05-08 | — | — | CN | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012053186-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | WO | disclosed |
| CN-101970430-A | Novel pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-09 | — | — | CN | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11154544-B2 | Amide derivatives as Nav1.7 and Nav1.8 blockers | SCN8A, SCN7A, SCN1A | TSHR 2692/4885MAPT 2729/4885ADORA3 2236/4885 |
| US-20140336377-A1 | ARYLAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN2B, SCN1B, SCN2A | TSHR 574/4885MAPT 3185/4885ADORA3 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.